Data Sheet 1_Therapeutic HIV-1 Tat vaccination promotes durable immune reconstitution and

Longitudinal clinical trial data from a 12-year extended follow-up of 161 ART-treated adults in South Africa who participated in a phase 2 trial of therapeutic HIV-1 Tat vaccination. The dataset includes measurements of anti-Tat antibody persistence, CD4+ T-cell counts, plasma HIV RNA, and total HIV DNA in peripheral CD4+ T cells. It was authored by Orietta Picconi and published on figshare in April 2026.

Use Cases

• Modeling the durability of anti-Tat antibody responses based on longitudinal seropositivity data.
• Analyzing CD4+ T-cell recovery trajectories over a decade based on repeated count measurements.
• Investigating the relationship between ART adherence and reservoir reduction based on total HIV DNA data.
• Comparing immune benefits between vaccinated and placebo groups based on stratified trial outcomes.

Strengths

• 12-year longitudinal follow-up provides a long-term view of vaccination effects.
• Data from 161 participants allows for stratified analysis by sex and ART adherence.
• Includes multiple key virological and immunological markers: anti-Tat antibodies, CD4+ counts, HIV RNA, and HIV DNA.

Limitations

• Column-level documentation is absent; field semantics must be inferred after download.
• Row count is unknown, which may limit suitability assessment.
• Data may reflect geographic bias inherent to the South African trial population.

Provenance

Source

figshare, authored by Orietta Picconi.

Collection Method

Data collected from a randomized, placebo-controlled phase 2 clinical trial (ISS T-003) and its 12-year extended follow-up.

Time Range

Follow-up period spans 12 years.

Freshness

Last updated 2026-04-10 05:58:59; freshness should be verified.

Geography

South Africa.